Pharmaceutical Commerce - April 2024 Issue (PDF)

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.

The April issue of Pharmaceutical Commerce examines the accelerated activity—and many ever-expanding layers—of temperature-sensitive transport in pharma.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.